Australia's most trusted
source of pharma news
Thursday, 09 May 2024
Posted 26 April 2024 AM
Omico has partnered with the Australian Translational Genomics Centre (ATGC) to expand its PrOSPeCT program to Queensland cancer patients.
The PrOSPeCT program (short for Precision Oncology Screening Platform enabling Clinical Trials Australia) has a $185 million public-private commitment with contributions from the Australian Government, NSW Government and industry partners, such as Roche.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.